Company ProfilePremium

Ivoclar Vivadent AG

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Ivoclar Vivadent AG - Company showcase

Year Founded & Workforce

1923

3,600 Employees

Ivoclar Vivadent AG logo

Ivoclar Vivadent AG Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Ivoclar Vivadent AG Overview

Ivoclar is one of the world's largest independent, family-owned dental materials and equipment companies, headquartered in Schaan, Liechtenstein, with more than a century of history. Its franchise is built on aesthetic restorative materials, above all the IPS e.max lithium disilicate glass-ceramic system launched in 2005, which the company states has been used in more than 230 million restorations worldwide, together with denture teeth (the company's original business), composites and adhesives for dentists, and ceramic furnaces (the Programat series, in which it claims global leadership). Ivoclar sells an integrated "materials + equipment + workflow + education" proposition to two core customer groups, dentists and dental laboratories, plus preventive-care teams. With roughly CHF 0.85 to 0.87 billion in annual turnover (FY2021 to FY2023), approximately 3,600 staff, five production sites and 71 education centres, it is a mid-sized premium player positioned between diversified US-listed dental conglomerates and smaller European specialists, and it is currently executing a cost-and-focus programme alongside a "Local4Local" regional-production strategy.


What the company does

Ivoclar develops, manufactures and markets dental materials, dental equipment, and related software/workflow integrations for dental practices and dental laboratories. The company frames its offer as "integrated solutions" across the treatment process, organised (per its public materials and Wikipedia) into four product areas:

  1. Direct Restoratives: composites (Tetric family), adhesives (Adhese, Adhese Universal / Adhese 2), curing lights (Bluephase), isolation devices (OptraGate, OptraDam), and preventive/care products (Cervitec, Fluor Protector, Proxyt and others under "Prevention & Care").

  2. Fixed Prosthetics: all-ceramic systems (IPS e.max Press, CAD, ZirCAD, Ceram, Ceram Art; IPS e.max Zirconia launched 2026), luting cements (Variolink, Multilink, SpeedCEM), ceramic furnaces (Programat), and legacy press-ceramic technology (IPS Empress, introduced 1991).

  3. Removable Prosthetics: denture teeth (SR Phonares and other SR lines), denture base materials (Ivobase), and the Ivotion digital denture system (monolithic denture milled from a single disc).

  4. Digital Dentistry: CAD/CAM milling machines (PrograMill series, including PrograMill 7 and 7 Pure launched May 2026), CAM software, validated partner workflows with 3Shape, exocad, vhf and SprintRay, and AR-based patient consultation software (from the Kapanu acquisition).

The company's own description

In its standard media boilerplate (2023 to 2026 releases), the company describes the Ivoclar Group as one of the world's leading manufacturers of integrated solutions for high-quality dental applications, built on a comprehensive portfolio of products, systems and services, strong research and development, and a commitment to education. Its stated mission is "Making People Smile." The corporate "About Us" page states that it serves dentists, dental technicians and dental hygienists, and characterises disruptive innovation as part of its DNA. No annual report is published, so there is no formal annual-report business description.

Business model and revenue model

Revenue streamNatureDisclosure
Consumable materials (ceramics, composites, adhesives, cements, denture teeth, prophylaxis)Recurring, replenishment-driven product salesSplit not disclosed; widely regarded as the bulk of revenue
Equipment (furnaces, milling machines, curing lights)Capital goods with installed-base pull-through of consumablesSplit not disclosed
Software / digitalCAM software, updates, AR consultation apps; largely bundledNot disclosed; no subscription revenue line reported
ServicesRepair, customer care (e.g. São Paulo repair centre), training via Ivoclar Academy—
LicensingMaterial/workflow validation programmes with machine makers (e.g. "Authorized Milling Partner")Commercial terms not disclosed

Independent characterisation. Ivoclar's economics resemble a "razor/razor-blade" materials franchise: equipment (Programat furnaces, PrograMill mills) and validated workflows lock laboratories and practices into proprietary consumables (IPS e.max blocks, ingots and discs). Its competitive moat is the IPS e.max brand plus clinical evidence (a company scientific report in December 2025 cited survival rates above 95%), extensive education infrastructure, and a strong dealer and laboratory channel. Revenue is product-based; there is no disclosed subscription or licensing line of material size.

Value-chain position

Ivoclar sits in upstream manufacturing and R&D, selling principally through dental distributors/dealers (e.g. full-service dental dealers in Europe and North America) and directly to large laboratories, with its own subsidiaries handling marketing, education and technical support. It does not operate clinics or laboratories itself. It is increasingly building downstream logistics (global distribution centre in Ellwangen, Germany; automated US warehouse in Amherst, New York; Leicester, UK; São Paulo, Brazil).

Customer types and end-markets

Customer typeProductsNotes
Dentists (general and aesthetic practices)Direct restoratives, adhesives, cements, chairside CAD/CAM blocks, curing lights, isolationThe "dentist business" grew 39.2% in FY2021 (company release)
Dental laboratories / techniciansCeramics, furnaces, mills, denture teeth, IvotionLab business grew 23.1% in FY2021, driven by digital solutions
Dental hygienists / prevention teamsPrevention & Care portfolioSeparate IDS 2025 stand for Prevention & Care
Implant/full-arch cliniciansZirconia and implant-supported restorative conceptsMALO CLINIC partnership (2025) targets All-on-4 workflows
Dental schools / studentsEducationIvoclar Summer School (since 2022); approx. 160 students from 31 countries in 2026

Strategy

Stated strategic themes (paraphrased from company releases; no annual report or investor day exists)

  1. Focus on core competencies and strategic priorities (March 2024 reorganisation): sharpen portfolio, cut costs, reduce workforce.

  2. Growth markets emphasis (Heinz's 2023 mandate): increased focus on growth markets and core products, while investing in future innovation.

  3. Local4Local (since 2023): move production and logistics closer to markets for supply-chain resilience, regulatory fit and customer proximity.

  4. Integrated end-to-end workflows and open digital ecosystem: validated partner machines and software rather than a closed proprietary stack.

  5. Education as a moat: Ivoclar Academy, 71 centres, Summer School, Media Connect (first edition 14 April 2026).

  6. Customer centricity: IDS 2025 messaging put customers at the centre.

Initiatives in the last 24 months (Oct 2024 to Oct 2026)

InitiativeDateTypeDetail
IDS 2025 dual presenceMar 2025CommercialSeparate main and Prevention & Care stands
MALO CLINIC partnership2,025PartnershipAll-on-4 / implant-supported restorative concepts; joint studies with IPS e.max zirconia
vhf validation expansionNov 2025EcosystemZ4 and E4 machines validated for IPS e.max CAD; starter-package vouchers for practices
Marketing leadership rebuildJul 2025OrganisationCMO appointed
IPS e.max 20-year campaignSep to Nov 2025BrandEvents in Leipzig and Vienna
Scientific Report Vol. 4Dec 2025Evidencee.max survival rates above 95%
IPS e.max Ceram ArtDec 2025ProductStain/glaze/structure paste line
Ivoclar Smile AwardJan 2026BrandGlobal case award for IPS e.max
OptraGate Dry Control; Adhese 2Mar 2026ProductDirect restorative upgrades
Ivoclar Media ConnectApr 2026CommunicationsFirst media event at the new campus
Shanghai production LOIApr 2026 (announced Jun 2026)FootprintProduction from 2028
IPS e.max Zirconia; PrograMill 7 / 7 PureMay 2026ProductFast-fire zirconia; new mill generation
New gingiva and tooth shadesJul 2026ProductPersonalised dentures
Anti-counterfeiting campaignJul 2026Brand protectionAction against counterfeit goods and unsafe trading channels
Amherst warehouse automation2026 (ongoing)LogisticsConversion to automated warehouse
"Simplify Your Filling Therapy"Sep 2026WorkflowDirect-restorative simplification

Cost programme

ProgrammeAnnouncedScopeTarget
Reorganisation and cost reduction4 Mar 2024Workforce reductions at several locations; approx. 240 employees affected globally; redundancy (social) plan in placeSavings target not disclosed

Sustainability/ESG commitments

No quantified public targets were located.

Medium-term financial targets / guidance

None publicly disclosed. The company has never published margin or growth targets. Its last outlook statement located (March 2022) described it as cautiously optimistic given geopolitical uncertainty.

Products & Services

Pricing models are not publicly disclosed by the company at group level; products are sold through dealers at list prices that vary by country. Launch years are given where verified; otherwise marked.

Fixed Prosthetics / All-Ceramics

ProductDescription & key capabilitiesTarget customerLaunch / latestNotes
IPS e.max (system)Lithium disilicate glass-ceramic family for crowns, veneers, inlays/onlays, bridges; company reports more than 230 million restorations (sales-based)Labs, dentists2005; 20th anniversary 2025Flagship franchise; Dec 2025 scientific report (Vol. 4) cites survival rates above 95%
IPS e.max CADMachinable lithium disilicate blocks ("blue blocks"), patented; indication range expanded at IDS 2013Chairside dentists, labs2005 introduction; expanded 2013Authorised milling partners: vhf N4+ (2024), Z4 and E4 (2025)
IPS e.max PressPressable ingotsLabsPress tech since 1991 (Empress)30 years of press technology celebrated (2021)
IPS e.max ZirCAD (incl. Prime, Prime Esthetic)Zirconia discs; Prime Esthetic launched 2021Labs2021 (Prime Esthetic)Updated features presented 2024
IPS e.max ZirconiaNew zirconia addition to the e.max family, developed with technicians; multiple fast-fire protocolsLabsMay 2026Planned use in MALO CLINIC implant studies
IPS e.max CeramVeneering ceramicLabs—Gingiva shades promoted 2025
IPS e.max Ceram ArtReady-to-use stain, glaze and structure pastes for monolithic, pressed and layered restorationsLabsDec 2025Showcased at LMT Lab Day West 2026
IPS EmpressLeucite-reinforced press ceramic (first press ceramic)Labs, dentists1,991Legacy line
Programat furnaces (e.g. P-series, CS-series)Press and firing furnaces; company claims global market leadershipLabs, chairsideOngoing (CS6 referenced)Installed-base anchor for consumables
Luting cements: Variolink, Multilink, SpeedCEMAdhesive and self-adhesive resin cementsDentists—Completes the ceramic workflow

Direct Restoratives and Prevention & Care

ProductDescriptionTarget customerLaunch / latest
Tetric family (incl. Tetric plus)Composite restoratives; 2025 YouTube "Smart proof" series promotes shrinkage behaviour of Tetric plusDentistsTetric plus: c.2025
Adhese 2Latest adhesive; dual-polymerisation capability for the VivaPenDentistsMar 2026
BluephaseLED curing lightsDentists—
OptraGate / OptraGate Dry ControlLip and cheek retractor; moisture control and accessDentistsDry Control: Mar 2026
"Simplify Your Filling Therapy" workflowIntegrated direct-filling workflow (company promotes "4 instead of 3 treatments" efficiency)DentistsSep 2026
Prevention & Care range (e.g. Cervitec, Fluor Protector, Proxyt)Varnishes, prophy pastesHygienistsOngoing; dedicated IDS 2025 stand

Removable Prosthetics

ProductDescriptionTarget customerLaunch / latest
Ivotion Denture SystemDigital monolithic denture milled from one disc in a single uninterrupted process; design in 3Shape or exocad; ACP product innovation award Nov 2020Labsc.2019 to 2020
Denture teeth (SR lines, e.g. Phonares)Premium denture teeth, the company's founding businessLabsOngoing
New gingiva and tooth shadesExtended shades for personalised prosthesesLabsJul 2026
IvobaseDenture base systemLabs—

Digital Dentistry

ProductDescriptionTarget customerLaunch / latest
PrograMill 7Five-axis mill; 1.5 kW spindle for IPS e.max CAD and titanium alloys; automatic wet/dry changeover without manual cleaning; 12-inch displayLabsMay 2026
PrograMill 7 PureCompact variant for in-house labs and clinicsIn-house labs, clinicsMay 2026
Earlier PrograMill (One, PM3, PM5, PM7)Prior generation mills launched under "Ivoclar Digital"Labs, chairsideFrom 2017
PrograMill CAM softwareMaterial-specific milling strategiesLabsOngoing
AR consultation app (Kapanu tech)Real-time 3D preview of treatment resultDentists2,019
Partner workflows3Shape, exocad, vhf, SprintRay, CaysterLabs, dentists2020 to 2025

Services

ServiceDescription
Ivoclar AcademyOnline platform (webinars, studies, virtual workshops) launched in the COVID period
ICDE / education centres71 centres worldwide; flagship in Schaan; e.g. Canada centre opened 2012
Ivoclar Summer SchoolAnnual student programme since 2022; 2026 held in ten countries; approx. 160 students from 31 countries
LAB. EVOLUTION. LIVE. Tour 2026Mobile digital-lab van touring Germany/Austria
Repair & customer caree.g. São Paulo repair centre (2024)

Financial Narrative

Disclosure reality

Ivoclar publishes only a single headline turnover figure (and sometimes headcount and regional growth rates) via an annual press release. Gross profit, EBIT, EBITDA, net income, EPS, dividends, balance-sheet and cash-flow data are not publicly disclosed. The last turnover release located is for FY2023 (published 4 March 2024). No FY2024 or FY2025 turnover was found in company releases, trade press or Liechtenstein media as of 7 October 2026.

Income statement (5-year)

Notes: FY2021 growth in CHF computed against the disclosed FY2020 turnover of CHF 640 million (842/640 minus 1 = 31.6%); the company's own currency-adjusted figure is 31.2%. FY2022 and FY2023 CHF growth rates are simple arithmetic on reported figures. FY2023 currency-adjusted growth was positive in all regions per the company, but no percentage was given.

Long-run turnover history (all disclosed data points)

Sources: ZWP/IDS Today 2013 (FY2012); Dental Community Mar 2015 (FY2014); Dental Community 2018 (FY2017); liechtenstein.li Mar 2019 (FY2018); liechtenstein.li Mar 2021 (FY2020); Ivoclar Mar 2022 (FY2021); Ivoclar/Dentistry Today Mar 2023 (FY2022); Ivoclar Mar 2024 (FY2023). FY2019 turnover was described as a then-record but an exact figure was not located; FY2013, FY2015 and FY2016 not located.

Commentary. Reported CHF turnover has been essentially flat in the CHF 810 to 870 million band since 2017, except for the 2020 COVID trough. The flatness masks positive local-currency growth: the company repeatedly reports currency-adjusted growth above market (e.g. +4.9% in FY2022) but strong-franc translation erodes it, as explicitly stated in the FY2023 release (sales increases in all regions, yet CHF revenue below prior year). The inflection to watch is FY2024 onward: the company announced a restructuring in March 2024 citing currency, geopolitics and disproportionate cost increases, and then stopped publishing turnover. Silence after a long tradition of annual releases is itself a data point; it is consistent with a period of flat-to-lower CHF revenue, but this cannot be verified and is flagged as interpretation only.

Cash flow

The only disclosed investment figure located: a planned global investment of approx. CHF 82 million for 2018, of which CHF 39 million at Schaan (FY2017 release). Visible capital projects since then (new Schaan HQ building opened 2023; Ellwangen distribution centre 2021; Leicester 2023; São Paulo 2024; Amherst automation ongoing; Shanghai plant from 2028) indicate sustained capex, but amounts are not disclosed.

Productivity proxy (computed from disclosed figures only)

Note: FY2023 uses the approx. 3,800 FTE figure from the March 2024 release; other company statements from the same period cite approx. 3,700, which would imply approx. CHF 231 thousand. The broadly flat revenue-per-employee ratio since 2017 underlines why management targeted cost and headcount in 2024.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Product Area Details

Product areaContents

Direct Restoratives

Composites, adhesives, curing lights, isolation, prevention & care

Fixed Prosthetics

All-ceramics, zirconia, cements, furnaces

Removable Prosthetics

Denture teeth, base materials, Ivotion

Digital Dentistry

Mills, CAM software, partner workflows, AR

Business (growth %, FY2021 vs FY2020, currency-adjusted where stated)

Business (growth %, FY2021 vs FY2020, currency-adjusted where stated)FY2021

Dentist business growth (%)

39.2

Laboratory business growth (%)

23.1

Group growth vs prior year (%)

31.2

Segment (CHF Mn) Overview

Segment (CHF Mn)FY2023

Group turnover (CHF Mn)

856

Revenue History

PeriodSales structureSource

Mar 2023

Christian Brutzer (CCO) responsible for the sales organisation of all markets

Dentistry Today (Mar 2023)

From 1 Jan 2024

Split into Mature Markets (Brutzer) and High Growth Markets (Mirco Stiehle: LATAM + APAC)

Ivoclar (Sep 2023)

2025 to 2026 (current website)

CCO North America (Chester Spivey) and CCO LATAM & APAC (Mirco Stiehle) listed in corporate management; no CCO Mature Markets listed

ivoclar.com About Us

Group Entities

EntityCountryRole

Ivoclar Vivadent AG

Liechtenstein

Parent, HQ, R&D, production

Ivoclar Vivadent GmbH

Germany (Ellwangen)

Sales subsidiary; global distribution centre

Ivoclar Vivadent, Inc. / Ivoclar Inc.

USA (Amherst, NY)

North American subsidiary

Wieland Dental + Technik / Wieland Dental Ceramics

Germany (Pforzheim)

Acquired 2012/13 (current status not disclosed)

Kapanu AG

Switzerland

AR software, acquired 2017 (current status not disclosed)

Manufacturing entities

Austria (Bürs), Italy (Naturns), Philippines (Manila), USA (Somerset NJ)

Production

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023

Revenue (CHF Mn)

842872856

Revenue growth reported in CHF (%)

31.63.6-1.8

Revenue growth currency-adjusted, company (%)

31.24.9—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Financials

MetricFY2012FY2014FY2017FY2018FY2020FY2021FY2022FY2023

Group turnover (CHF Mn)

658761809810640842872856

Valuation Snapshot

MetricValue

CAGR FY2012 to FY2023 (11 years, CHF)

approx. 2.4%

CAGR FY2017 to FY2023 (6 years, CHF)

approx. 0.9%

CAGR FY2021 to FY2023 (2 years, CHF)

approx. 0.8%

Key Financials (FY2017–FY2023)

MetricFY2017FY2021FY2023

Turnover (CHF Mn)

809842856

Employees (year-end headcount or FTE as disclosed)

3,5963,5483,800

Turnover per employee (CHF K)

225237225

Region growth (%)

Region growth (%)FY2014FY2017FY2021

Europe / EMEA growth (%)

3.41.531.0

North America growth (%)

1.43.936.0

Latin America growth (%)

14.514.761.3

Asia Pacific growth (%)

5.69.717.2

Orient & Africa growth (%)

27.0——

Group growth, local currency (%)

4.43.331.2

Capital Markets

ItemStatus

Share price performance (1/3/5-year)

Not applicable (no listed shares)

Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B)

Not applicable / not publicly disclosed

Peer multiples

Not computed here (Ivoclar has no market value to compare)

Analyst consensus

None (no sell-side coverage)

Dividend history and policy

Not publicly disclosed (distributions to family owners, if any, are private)

Credit ratings (Moody's, S&P, Fitch)

None located; no public bonds identified

Public debt instruments

None identified

Analyst Conclusions

Management guidance

No numeric guidance is published. Qualitative direction from 2023 to 2026 releases: focus on core products and growth markets, cost discipline after the 2024 reorganisation, regionalised production (Local4Local), continued product-led innovation (e.max Zirconia, PrograMill 7), and education-driven customer intimacy.

Consensus growth expectations

None exist (no analyst coverage). Industry context: digital dentistry projected at approx. 9.6% CAGR to 2031 (Mordor Intelligence, 2026).

Bull case

  1. e.max into zirconia: extending the strongest brand in all-ceramics into fast-fire zirconia (May 2026) can recapture share lost to low-cost monolithic zirconia.

  2. Leaner cost base: headcount down from approx. 3,700 to 3,800 (2023) to approx. 3,600 (2026) after the 2024 programme should lift margins if local-currency growth resumes.

  3. Footprint and channel investments maturing: Ellwangen, Leicester, São Paulo, Amherst automation and Shanghai (2028) should improve service levels, tariff resilience and access to the high-growth markets that historically grew fastest.

Bear case

  1. Structural CHF stagnation: reported revenue has barely moved since 2017 (approx. 0.9% CAGR to 2023), and disclosure stopped thereafter.

  2. Commoditisation: generic lithium disilicate, Chinese zirconia and counterfeits erode price premiums on the core franchise.

  3. Sub-scale in digital: without owning scanners, CAD or printers, Ivoclar depends on partners whose ecosystems may favour rival materials, while larger peers bundle implants, scanners and consumables.

Key catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Any FY2025/FY2026 turnover disclosure (typically March)Resumption would signal confidence; continued silence would reinforce caution
IDS 2027 (Cologne, March 2027) preparations and launchesPrimary launch platform
Adoption of IPS e.max Zirconia and PrograMill 7 in US/EU labsTests the zirconia extension thesis
Shanghai site progress (permits, construction)Execution of Local4Local
Further management or board changesStability after several transitions
Additional production consolidation in EuropeMargin vs disruption trade-off
MALO CLINIC study outputsCredibility in implant-restorative space
CHF exchange rate vs EUR/USDLargest single swing factor for reported revenue
Counterfeit enforcement outcomesBrand integrity

Analyst verdict

Ivoclar is a high-quality, innovation-rich but financially opaque dental materials company whose investment case, for any counterparty (supplier, distributor, partner, acquirer or competitor), rests on the durability of the IPS e.max franchise and its ability to convert a century of materials science into relevance in a digitising, increasingly commoditised market. The verifiable record is mixed. On one side, the company owns arguably the best-known brand in all-ceramic dentistry, a claimed leadership position in ceramic furnaces, more than 240 R&D staff, 71 education centres, and a demonstrated ability to rebound from shocks (COVID trough of CHF 640 million in 2020 to a record CHF 872 million in 2022). On the other side, reported CHF turnover has been effectively flat for six years, revenue per employee has not improved since 2017, the company needed a restructuring in 2024 affecting roughly 240 roles, leadership has turned over repeatedly since 2019, and it has stopped publishing even headline turnover after FY2023.

Management's response is coherent: protect the core by extending e.max into zirconia, refresh the equipment platform (PrograMill 7), partner rather than build in scanning and printing, regionalise production through Local4Local (including a first Chinese plant from 2028), and invest in education and evidence. The constraint is scale: Ivoclar competes against listed peers three to four times its size with integrated implant and scanner ecosystems, and its CHF cost base amplifies every currency move.

Net assessment: a stable, strategically well-positioned but low-growth specialist in transition, with execution on zirconia, China and cost efficiency as the decisive variables.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleBornJoinedIn corporate management sincePrior roles / notes

Markus Heinz

Chief Executive Officer

1,9691985

2015 (CEO since 2023)

1985 to 2011 Ivoclar Manufacturing Naturns (Italy); 2011 to 2015 MD Naturns; later Group COO; background in production, supply chain, organisational development

Michael Bickel

Chief Financial Officer

1,97120232023

Finance and operations executive with global experience; succeeded Franz Berger (CFO 2012 to mid-2024)

Martin Frontull

Chief Marketing Officer

1,98720092025

Previously Managing Director Germany (Ellwangen) until July 2025

Dr Thomas Hirt

Chief Technology Officer

1,96720102013

Leads R&D

Chester Spivey

Chief Commercial Officer North America

1,96519982025

Long-tenured North America executive

Mirco Stiehle

Chief Commercial Officer LATAM & APAC

1,97120192024

Head of LATAM from Dec 2019; prior roles in medical device/dental industry in Germany, Japan and the US

Stefan Riegler

Chief Production Officer

1,98119972025

Spokesperson for Local4Local / Shanghai project

Executive Leadership Team — Dr Karen J. Huebscher

NameRoleBackground (public sources)

Dr Karen J. Huebscher

President of the Supervisory Board

PhD (ETH Zurich), MBA (IMD); Vice Chair of Sandoz Group AG (since 2023); former CEO of Solvias (2014 to 2021); former Tecan board member; long Novartis career (investor relations, Vaccines & Diagnostics executive committee, M&A); founder of FibulaMedical (2012)

Christina Zeller

Vice President of the Supervisory Board

Owner-family representative; joined board 2019; led CSR efforts

Dr Friederike Hoffmann-Sieg

Member

Digitalisation expertise; joined 1 Sep 2022

Prof Dr Peter Leibfried

Member

Academic (accounting/finance profile)

Prof Dr-Ing Wolfgang Reitzle

Member

Former Linde CEO and chairman; former Continental chairman

Governance Overview

FeatureStatus

Chair/CEO separation

Yes; non-executive Supervisory Board chaired by an external professional

Board independence

Majority external members (Huebscher, Hoffmann-Sieg, Leibfried, Reitzle); one family representative (Zeller)

Gender

3 of 5 board members are women (Huebscher, Zeller, Hoffmann-Sieg)

Board & Management Changes

DateChangeContext

1 Jul 2019

Gabathuler succeeds Ganley as CEO

Generational transition; Ganley to board

Mar 2023

Heinz succeeds Gabathuler

Gabathuler left to explore start-up/other options; Heinz mandated to focus on growth markets and core products

Sep/Dec 2023

Bickel named CFO; Stiehle to corporate management (from 1 Jan 2024)

Sales split into mature vs high-growth markets

Jun 2024

Franz Berger departs after 12 years as CFO

Planned handover

1 Jul 2025

Frontull becomes CMO (Heinz had led marketing on an interim basis); Süßmuth becomes MD Germany

Marketing leadership re-filled

2025

Spivey (CCO NA) and Riegler (CPO) join corporate management

Commercial and production focus

Major Shareholders

HolderStake

Zeller family (descendants of Adolf Schneider)

Controlling / effectively 100% (exact stake not disclosed)

Institutional holders

None (not listed)

Competitive Landscape

Key Competitors

CompetitorOwnershipOverlap with Ivoclar

Dentsply Sirona

Listed (Nasdaq: XRAY)

Restoratives, CAD/CAM (CEREC), ceramics (Celtra), dentures, equipment

Envista (Kerr, Nobel Biocare, Spark)

Listed (NYSE: NVST)

Composites, adhesives, cements, implants

Straumann Group

Listed (SIX: STMN)

Digital/CAD-CAM, zirconia, implants; scanning

Solventum (ex-3M Health Care; dental unit)

Listed (NYSE: SOLV)

Composites (Filtek), adhesives, cements, CAD/CAM blocks

GC Corporation

Private (Japan)

Restoratives, ceramics (Initial), CAD/CAM blocks

Kulzer (Mitsui Chemicals)

Subsidiary of listed parent

Composites, denture materials, lab

VOCO

Private (Germany)

Composites, adhesives

Kuraray Noritake Dental

Subsidiary of Kuraray (listed)

Adhesives (Clearfil), zirconia (Katana), ceramics

VITA Zahnfabrik

Private (Germany)

Denture teeth, ceramics, furnaces

Amann Girrbach

Private (Austria)

Lab CAD/CAM, zirconia, furnaces

Zirkonzahn

Private (Italy)

Zirconia, mills

Coltene

Listed (SIX: CLTN)

Restoratives, endo, infection control

Shofu

Listed (Tokyo)

Restoratives, ceramics

GC/other Asian makers, Upcera, Aidite (China)

Various

Low-cost zirconia, a pricing pressure source

Peer Comparison FY2024

MetricIvoclar (FY2023)Straumann (FY2024, approx.)Dentsply Sirona (FY2024, approx.)Envista (FY2024, approx.)

Revenue (approx.)

CHF 856M

approx. CHF 2.5bn

approx. USD 3.8bn

approx. USD 2.5bn

Revenue growth

-1.8% reported CHF

Double-digit organic (approx.)

Approx. -4% reported

Approx. flat to slightly down

Operating margin

—

Core EBIT approx. mid-20s %

Adjusted mid-to-high teens %

Adjusted low teens %

R&D intensity

n/d (240+ R&D staff)

Approx. 5%

Approx. 4 to 5%

Approx. 5%

Ownership

Private family

Listed

Listed

Listed

Competitive Advantages & Vulnerabilities

AdvantagesVulnerabilities

IPS e.max brand and clinical evidence (more than 230M restorations; above 95% survival in company report)

Lithium disilicate patents mature; generic/low-cost lithium disilicate and zirconia from Asian makers; counterfeit products (company campaign Jul 2026)

Installed base of Programat furnaces and validated workflows

Late in digital equipment vs Dentsply Sirona/3Shape; mill development delays cited in 2018

Education network (71 centres) and lab loyalty

Scale disadvantage vs USD 2.5 to 4bn peers

Family ownership enables long-term investment

Opaque disclosure; no public capital-market access

Diversified production (5 sites, China planned)

CHF cost base and translation exposure (explicitly cited in 2024)

Open-partner model (3Shape, exocad, vhf, SprintRay)

Dependence on partners for scanning/printing; no implant business

Recent Developments

Items not found in the period: guidance revisions, litigation, regulatory actions, additional layoffs, M&A, or published FY2024/FY2025 results.

Company Snapshot

$952.2M

Revenue

3,600

Employees

1923

Founded

Schaan, Liechtenstein

Headquarters

SWOT Analysis

Strengths

  • Category-defining franchise: IPS e.max, launched 2005, reported in more than 230 million restorations (company sales-based figure, 2025).
  • Clinical evidence: Scientific Report Vol. 4 (Dec 2025) cites survival rates above 95% for IPS e.max.
  • Equipment leadership: company claims global market leadership in ceramic furnaces (Programat series, 2023 centenary release).
  • Education infrastructure: 71 education centres; Summer School reaching approx. 160 students from 31 countries in 2026.
  • R&D depth: more than 240 R&D staff; 341 patents filed per CB Insights; Feb 2026 grant.
  • Resilience: FY2020 decline (-17.7% FX-adjusted) followed by record FY2021 (CHF 842M, +31.2%) and record FY2022 (CHF 872M).
  • Global footprint: 56 subsidiaries and branches; sales in approx. 130 countries; 5 production sites.

Weaknesses

  • Stagnant CHF revenue: CHF 809M (FY2017) vs CHF 856M (FY2023), approx. 0.9% CAGR.
  • Flat productivity: approx. CHF 225 thousand revenue per employee in both FY2017 and FY2023.
  • Disclosure opacity: no FY2024/FY2025 turnover published; no profit data ever disclosed.
  • Digital execution history: FY2018 growth shortfall attributed by the company to delayed milling-machine development.
  • Leadership churn: three CEOs since 2019 (Ganley, Gabathuler, Heinz); CFO change 2023/24; CMO seat vacant until July 2025.
  • No implant franchise: relies on partnerships (MALO CLINIC) for implant-restorative exposure, unlike Straumann/Envista.

Opportunities

  • Zirconia extension: IPS e.max Zirconia (May 2026) brings the e.max brand into the fastest-growing material class.
  • China localisation: Shanghai production from 2028 to serve China more efficiently and mitigate trade barriers.
  • Implant-supported restorations: MALO CLINIC All-on-4 collaboration and zirconia studies.
  • 3D printing: SprintRay partnership (Apr 2024) adds printed-materials pathway.
  • Chairside channel expansion: vhf N4+, Z4, E4 validations broaden e.max CAD reach.
  • High-growth regions: LATAM historically the fastest-growing region (61.3% in 2021); dedicated CCO and São Paulo hub since 2024.

Threats

  • Currency: strong CHF reduced FY2023 reported turnover despite growth in all regions.
  • Cost inflation and geopolitics: cited as reasons for the March 2024 restructuring.
  • Low-cost Asian competition in zirconia and lithium disilicate.
  • Counterfeits: company escalated anti-counterfeiting messaging in July 2026.
  • Scale competitors: Dentsply Sirona, Straumann and Envista each multiple times Ivoclar's revenue with integrated scanner/implant ecosystems.
  • Ecosystem dependence: reliance on 3Shape, exocad, vhf and SprintRay for key digital steps; partners may favour other materials.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
25 to 29 Mar 2025IDS 2025, Cologne: two stands (main hall 11.3; Prevention & Care hall 10.1)Signals elevated priority for Prevention & Care
1 Jul 2025Jan Süßmuth named MD Germany; Martin Frontull becomes global CMOFills marketing leadership gap
Jul 2025Ivoclar Joy CSR site opens on Palawan, PhilippinesCSR footprint in a production country
2025 (H2)Strategic partnership with MALO CLINIC signed in SchaanEntry into implant-restorative concepts
13 Sep 2025IPS e.max 20-year event, LeipzigBrand reinforcement
Nov 2025vhf Z4/E4 validation for IPS e.max CAD; software update from Nov 2025Broadens chairside channel
22 Nov 2025IPS e.max 20-year event, ViennaBrand reinforcement
2025Tetric plus "Smart proof" campaign; Ivotion and "4 instead of 3 treatments" contentDirect-restorative marketing push
12 Dec 2025Scientific Report Vol. 4 on IPS e.max (survival rates above 95%)Clinical evidence moat
22 Dec 2025IPS e.max Ceram Art launchedLab characterisation product
7 Jan 2026Ivoclar Smile Award introducedCustomer engagement
9 Mar 2026OptraGate Dry ControlPractice efficiency
26 Mar 2026Adhese 2 with VivaPen dual-polymerisationAdhesive upgrade
14 Apr 2026First Ivoclar Media Connect at new Schaan campus; company cites approx. 3,600 employeesConfirms post-restructuring headcount
Apr 2026LOI signed for Shanghai production site (Xinzhuang Industrial Park, Minhang)First China production; Local4Local
4 May 2026PrograMill 7 and 7 Pure launchedNext-gen mill platform
5 May 2026Summer School 2026 announced for ten countriesEducation pipeline
5 May 2026e.max Zirconia and Ceram Art showcased at LMT Lab Day West (US)US lab push
20 May 2026IPS e.max Zirconia launchedExtends e.max into zirconia segment
2026LAB. EVOLUTION. LIVE. Tour (Germany/Austria)Field marketing with VR PrograMill experience
17 Jun 2026Local4Local release: production network detailed (Schaan, Bürs, Manila, Naturns, Somerset), Shanghai from 2028; Amherst automationFootprint strategy disclosed
2 Jul 2026New gingiva and tooth shades for personalised prosthesesRemovable portfolio
17 Jul 2026Anti-counterfeiting initiative publicisedBrand/IP protection; signals grey-market pressure
27 Jul 2026US lab podcast promotion of e.max Zirconia fast-fire and PrograMill 7US commercial push
25 Aug 20262026 Ivoclar Smile Award winners announcedEngagement
17 Sep 2026Summer School 2026: approx. 160 students from 31 countriesEducation
24 Sep 2026Job postings in Schaan still cite 3,600 to 3,700 employeesHeadcount stable
28 Sep 2026"Simplify Your Filling Therapy" workflow presentedDirect-restorative simplification

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment: Group turnover was CHF 856 Mn in FY2023.
Ivoclar Vivadent AG — Revenue by Segment
Series (CHF Mn)FY2023
Group turnover856

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Ivoclar, "About Us" (corporate management, supervisory board, key figures)
  2. Ivoclar, "Securing future success" (FY2023 results, reorganisation), 4 Mar 2024
  3. Ivoclar, "Significant growth for the Ivoclar Group" (FY2021), 17 Mar 2022
  4. Dentistry Today / Aegis, FY2022 results and CEO change, Mar 2023
  5. Ivoclar, "A Century of Innovation", 5 Jan 2023
  6. Ivoclar, "A bright start to a new century", Jan 2024
  7. Ivoclar, "Ivoclar expands Corporate Management team", 13 Sep 2023
  8. Ivoclar, IDS 2025 release
  9. Ivoclar, Media Connect release, 16 Apr 2026
  10. Ivoclar, PrograMill 7 release, 4 May 2026
  11. Ivoclar, MALO CLINIC partnership, 2025
  12. Ivoclar, SprintRay partnership, 2024
  13. Ivoclar, Supervisory Board expansion, 1 Sep 2022
  14. Dental Tribune, Ivoclar news archive
  15. Dental Tribune, Local4Local / Shanghai, 17 Jun 2026
  16. Dental Tribune, PrograMill 7 launch, May 2026
  17. Dental Tribune, vhf cooperation
  18. Dental Tribune, 240 job cuts
  19. Liechtenstein Marketing, centenary history
  20. Liechtenstein Marketing, Heinz named CEO
  21. Liechtenstein Marketing, FY2020 results
  22. Liechtenstein Marketing, FY2018 results
  23. Liechtenstein Marketing, management reorganisation 2023
  24. ZWP Online, MD Germany / CMO appointments, 11 Jul 2025
  25. zm-online, 20 years of IPS e.max
  26. Dental Community, FY2017 results
  27. Dental Community, FY2014 results
  28. Dental Community, 2019 leadership transition
  29. Dental Community, Kapanu acquisition
  30. Dental Products Report, Wieland acquisition
  31. Lincoln International, Wieland transaction
  32. Wikipedia, "Ivoclar"
  33. CB Insights, Ivoclar Vivadent profile
  34. Great Place to Work Switzerland, Ivoclar Vivadent AG
  35. IMBB-FORTH, Karen J. Huebscher biography (2025)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.